A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954
A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
研究概览
详细说明
The drug being tested in this study is called TAK-954. This study will evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
The study will enroll approximately up to 40 participants. Participants will be enrolled in one of the 5 treatment groups based on their renal impairment which will be determined based on Cockcroft and Gault (CG) equation as follows:
- Group A TAK-954 0.2 mg: Healthy Participants
- Group B TAK-954 0.2 mg: Mild Renal Impairment
- Group C TAK-954 0.2 mg: Moderate Renal Impairment
- Group D TAK-954 0.2 mg: Severe Renal Impairment or End-stage Renal Disease (ESRD) Without Hemodialysis
- Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD) With Hemodialysis
All participants in groups A to D will receive a single dose of TAK-954 and two single doses in Group E.
Enrollment in Group B (Mild) and Group E (ESRD requiring dialysis) will be based on assessment of safety and available PK data from Group C and Group D respectively.
This multi-center trial will be conducted in Czech Republic and Hungary. The overall time to participate in this study is approximately 8 weeks. Participants in Groups A to D will remain confined to clinic for 3 days. For both treatments, participants in Group E requiring dialysis will remain confined to clinic for 3 days. All participants will make a final visit to the clinic 10-14 days after receiving their last dose for a follow-up assessment.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- All participants: Male and female participants (non-childbearing potential) who are aged 18 to 75 years, inclusive, with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m^2).
- Group A: As much as possible, the healthy participants with normal renal function (creatinine clearance [CLcr] greater than or equal to [>=] 90 milliliter per minute [mL/min]) should be comparable to participants with renal impairment with respect to median age and weight (approximately 50 percent [%] of healthy participants on each side of the median age and weight of currently enrolled renally-impaired participants grouped together), sex, and race. This will be decided by the investigators in discussion with Takeda.
Groups B to E: Participants who have stable RI, defined as no clinically significant change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.
- Group B: Participants with mild RI (CLcr 60 to less than [<] 90 mL/min).
- Group C: Participants with moderate RI (CLcr 30 to <60 mL/min).
- Group D: Participants with severe RI or ESRD but not requiring dialysis (CLcr <30 mL/min).
- Group E: Participants with ESRD requiring dialysis (<15 mL/min requiring hemodialysis at least 3 times/week, and having been on the same dialysis treatment regimen for at least 1 month before trial entry).
- Participants should be on a stable drug regimen defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) before dosing with TAK-954.
Exclusion Criteria:
All participants:
- Are renal allograft recipients within 1 year of screening.
- Have a history of gastrointestinal (GI) motility disorder or intestinal obstruction.
- Have urinary incontinence without catheterization.
- Group A: Participants who, in the discretion of the investigator, have a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
Groups B to E:
- Receive dialysis other than intermittent dialysis (except Group E).
- Have renal disease secondary to hepatic disease (hepatorenal syndrome).
- At the discretion of the investigators, have any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Group A TAK-954 0.2 mg: Healthy Participants
Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 静脉输注。
|
实验性的:Group B TAK-954 0.2 mg: Mild Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 静脉输注。
|
实验性的:Group C TAK-954 0.2 mg: Moderate Renal Impairment
Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 静脉输注。
|
实验性的:Group D TAK-954 0.2 mg: Severe Renal Impairment
Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
|
TAK-954 静脉输注。
|
实验性的:Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)
Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
|
TAK-954 静脉输注。
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Groups A, C and D; Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free)
大体时间:Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC(0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Post-dose for TAK-954 (Free and Total)
大体时间:Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 72 hours) post-infusion
|
Groups A, C and D; AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-954 (Free and Total)
大体时间:Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-954 (Free and Total)
大体时间:Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 120 hours) post-infusion
|
Groups A, C and D; Ae: Amount of TAK-954 Excreted in Urine
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 1
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Ae: Amount of TAK-954 Excreted in Urine in Period 2
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; Fe: Fraction of TAK-954 Excreted in Urine
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 1
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; Fe: Fraction of TAK-954 Excreted in Urine in Period 2
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Groups A, C and D; CLR: Renal Clearance for TAK-954
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 1
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLR: Renal Clearance for TAK-954 in Period 2
大体时间:Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 24 hours) post-infusion
|
Group E; CLD: Clearance of Dialysate for TAK-954 in Period 2
大体时间:Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
Day 1 pre-infusion and at multiple time points (up to 4 hours) post-infusion
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- TAK-954-1007
- U1111-1196-9206 (注册表标识符:WHO)
- 2017-000715-16 (EudraCT编号)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
TAK-954的临床试验
-
Millennium Pharmaceuticals, Inc.完全的